Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.48 |
| ▸ | POLG | P54098 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201132 | 1.00 | POLB (0.50) | POLBPDE3ALMNACACNA1FALB | |
| SCHEMBL28799641 | 0.91 | POLB (0.53) | POLBPDE3ALMNACACNA1FALB | |
| SCHEMBL5666376 | 0.91 | POLB (0.53) | POLBPDE3ALMNACACNA1FALB | |
| SCHEMBL7794947 | 0.89 | POLB (0.51) | POLBPDE3ALMNACACNA1FALB | |
| SCHEMBL3449196 | 0.89 | POLB (0.51) | POLBPDE3ALMNACACNA1FALB | |
| SCHEMBL51649 | 0.88 | POLB (0.50) | POLBPDE3ALMNACACNA1FALB | |
| SCHEMBL3178721 | 0.88 | POLB (0.50) | POLBPDE3ALMNACACNA1FALB | |
| SCHEMBL4199985 | 0.88 | POLB (0.50) | POLBPDE3ALMNACACNA1FALB | |
| SCHEMBL13471863 | 0.88 | POLB (0.50) | POLBPDE3ALMNACACNA1FALB | |
| SCHEMBL3896397 | 0.86 | POLB (0.48) | POLBPDE3ALMNACACNA1FALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110234319-A | The composition and its application method of benzamide and reactive compound | 转化药物开发有限责任公司 | 2019-09-13 | — | — | CN | claimed |
| US-8470522-B2 | Three-dimensional culture containing human articular chondrocytes with induced terminal differentiation changes and preparation process and uses of the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-06-25 | — | — | US | claimed |
| EP-2207786-A1 | 2 ' -FLU0R0-2 ' -DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | Eisai Inc. (US) | 2010-07-21 | — | — | EP | claimed |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | claimed |
| WO-2009052287-A1 | 2 ' -FLU0R0-2 ' -DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | EISAL CORPORATION OF NORTH AMERICA (US) | 2009-04-23 | — | — | WO | claimed |
| US-20080026362-A1 | Three-dimensional culture containing human articular chondrocytes with induced terminal differentiation changes, and preparation process and uses of the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2008-01-31 | — | — | US | claimed |
| US-20060253263-A1 | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy | MESHKIN BRIAN J | 2006-11-09 | — | — | US | claimed |
| EP-1156827-A2 | TREATMENT OF NEOPLASTIC DISEASES BY RADIATION | Halogenetics, Inc. (US) | 2001-11-28 | — | — | EP | claimed |
| WO-2000051639-A9 | TREATMENT OF NEOPLASTIC DISEASES BY RADIATION | HALOGENETICS INC (US) | 2001-10-25 | — | — | WO | claimed |
| WO-2000051639-A2 | TREATMENT OF NEOPLASTIC DISEASES BY RADIATION | HALOGENETICS, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| EP-0504279-B1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | CHEMGEN CORP (US) | 1997-07-09 | — | — | EP | claimed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | claimed |
| EP-0504279-A4 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | — | 1993-02-17 | — | — | EP | claimed |
| EP-0504279-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES. | CHEMGEN CORP (US) | 1992-09-23 | — | — | EP | claimed |
| WO-1991009130-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | CHEMGEN CORPORATION (US) | 1991-06-27 | — | — | WO | claimed |
| EP-0287128-A1 | Antitumor agent | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1988-10-19 | — | — | EP | claimed |
| US-20260103746-A1 | PROCESS FOR THE PRODUCTION OF CLOSED LINEAR DNA | TYRIS THERAPEUTICS S L (ES) | 2026-04-16 | — | — | US | disclosed |
| CN-112834678-B | Method for detecting concentration of 11 antitumor drugs in serum | 南京品生医学检验实验室有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-1991009130-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | CHEMGEN CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
| EP-0287128-A1 | Antitumor agent | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | DUT, TYMP, DPYD | POLB 123/4885PDE3A 944/4885LMNA 1274/4885 |
| US-20260103746-A1 | PROCESS FOR THE PRODUCTION OF CLOSED LINEAR DNA | POLM, POLL, POLB | POLB 3/4885PDE3A 2760/4885LMNA 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.